Alec Broers becomes chairman of Bio Nano Consulting
Brings extensive industry, academic and scientific expertise to company
Broers has extensive industry, academic and scientific expertise and was chairman of the House of Lords Science and Technology Select Committee between 2004 and 2007.
At Bio Nano Consulting he will facilitate ongoing partnerships between academia and the wider life science and technology industries.
Educated at Melbourne University and the University of Cambridge, Broers subsequently worked in r&d at IBM laboratories in the US for 19 years, ultimately taking responsibility for the company’s chip development.
Broers returned to the UK in 1984 as head of Electrical Engineering at Cambridge University and Fellow of Trinity College. He subsequently became head of the Department of Engineering and Master of Churchill College.
More recently, Broers was Vice Chancellor of Cambridge University and president of the Royal Academy of Engineering from 2001 to 2006. He was knighted in 1998 for services to education before being made a life peer in 2004.
Bio Nano Consulting is a joint venture of Imperial College London and University College London that specialises in solutions to industry across the life sciences and technology sectors.
You may also like
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results